Fortis Healthcare (India) today said it has acquired a majority stake in Singapore-based diagnostic firm RadLink-Asia Pte Ltd for 62.9 million Singapore dollar (about Rs 245 crore).

"Fortis Healthcare Singapore Pte Ltd, company's offshore subsidiary, has acquired 85 per cent stake in RadLink-Asia Pte Ltd, an outpatient diagnostic and molecular imaging chain in Singapore, for a purchase consideration of S62.9 million dollar," the domestic healthcare major said in a filing to the BSE.

The Indian firm said this transaction will provide Fortis Healthcare a strong foothold in the premium diagnostics and molecular imaging segment in one of South East Asia's most attractive markets.

Fortis further said the investment will provide a complementary platform to its upcoming specialty hospital on Adam Road in Singapore.

Radlink has four main business segments -- diagnostic imaging, molecular imaging, cyclotron (radio isotopes manufacturing) and GP clinics, the filing said.

Reacting to the announcement, shares of Fortis rose by 2.29 per cent to trade at Rs 107 apiece on the BSE in late morning trading.